EcoDrugPlus

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSCCRG00000014634
Gene Symbol: AGTR1
1 Cross references
199 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSCCRG00000055075
Gene Symbol: AGTR2
1 Cross references
186 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSCCRG00000071870
Gene Symbol: AGTR2
1 Cross references
186 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSCCRG00000071118
Gene Symbol: APLNR2
1 Cross references
172 Possible Orthologues:

Arachidonate 12-Lipoxygenase

Ensembl ID : ENSCCRG00000012385
Gene Symbol: ALOX12
1 Cross references
195 Possible Orthologues:

Arachidonate 12-Lipoxygenase

Ensembl ID : ENSCCRG00000039761
Gene Symbol: ALOX12
1 Cross references
197 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSCCRG00000072124
Gene Symbol: ALOX5AP
1 Cross references
197 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSCCRG00000027047
Gene Symbol: ALOX5AP
1 Cross references
198 Possible Orthologues:

Arginine Vasopressin Receptor 1aa

Ensembl ID : ENSCCRG00000058583
Gene Symbol: AVPR1AA
1 Cross references
192 Possible Orthologues:

Arginine Vasopressin Receptor 1aa

Ensembl ID : ENSCCRG00000031448
Gene Symbol: AVPR1AA
1 Cross references
192 Possible Orthologues:

Arginine Vasopressin Receptor 1ab

Ensembl ID : ENSCCRG00000041839
Gene Symbol: AVPR1AB
1 Cross references
193 Possible Orthologues:

Arginine Vasopressin Receptor 1ab

Ensembl ID : ENSCCRG00000002853
Gene Symbol: AVPR1AB
1 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).